Compound Deep-Dive

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome. First described by Dr. Changhan Lee and colleagues at the University of Southern California in 2015, MOTS-c represents a class of signaling molecules called mitochondrial-derived peptides (MDPs) — peptides encoded within the mitochondrial DNA that function as retrograde signaling molecules, communicating from mitochondria back to the nucleus and other cellular compartments.

This discovery was significant because it challenged the traditional view of mitochondria as purely energy-producing organelles. The identification of MOTS-c and other MDPs demonstrated that mitochondria actively participate in cellular signaling and metabolic regulation through peptide-mediated communication.

Mechanism of Action

AMPK Pathway Activation

The primary documented mechanism of MOTS-c involves activation of AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. Published research has shown that MOTS-c activates AMPK by modulating the folate-methionine cycle, which indirectly affects the cellular AMP:ATP ratio. This is distinct from direct AMPK activators like AICAR, which mimic AMP allosterically.

Nuclear Translocation

A particularly notable finding is that MOTS-c has been observed to translocate to the nucleus under metabolic stress conditions. Once in the nucleus, it interacts with transcription factors involved in antioxidant response and metabolic gene regulation. This nuclear translocation has been documented in both cell culture and mouse models, representing a novel signaling paradigm for a mitochondrial-encoded peptide.

Research Applications

Metabolic Signaling Models

The most active area of MOTS-c research involves metabolic regulation. In mouse models, MOTS-c administration has been associated with improved glucose homeostasis, increased insulin sensitivity, and prevention of diet-induced obesity. These effects appear mediated through the AMPK pathway and downstream metabolic gene regulation.

Exercise Biology

MOTS-c has been described as an “exercise mimetic” in research contexts — meaning it activates some of the same metabolic pathways that physical exercise engages. Published studies have shown that circulating MOTS-c levels increase in response to exercise in humans, and that exogenous MOTS-c administration in sedentary mice produces some metabolic adaptations similar to those seen with exercise training.

Aging Research

Because mitochondrial function declines with age, and because endogenous MOTS-c levels appear to decrease in older organisms, the peptide has attracted interest in aging research. Studies in aged mice have shown that MOTS-c treatment improved physical capacity and metabolic parameters. However, this research is in early stages and no conclusions about human aging should be drawn from these animal models.

Current Limitations

MOTS-c research is newer than most peptide fields — the initial discovery paper was published in 2015. While the mechanistic work is compelling, the total volume of published research is smaller than longer-established peptides like BPC-157 or Thymosin Beta-4. Replication across independent laboratories is ongoing.

Additionally, the pharmacokinetics of exogenous MOTS-c in vivo are not fully characterized. Questions remain about bioavailability, half-life, and optimal dosing parameters in research models.

Specifications

Form: Lyophilized powder. Purity: ≥98% (HPLC). Storage: -20°C. Available strength: 10 mg.

MOTS-c from Vial & Error Labs ships with lot-specific COA and SDS documentation. For research use only.

What is TB-500?

TB-500 is a synthetic peptide fragment corresponding to the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in cell motility, differentiation, and survival. CAS number: 77591-33-4. It is supplied as a lyophilized powder for in vitro and preclinical research.

Thymosin Beta-4 was first isolated from the thymus gland in the 1960s and has since been identified in virtually all mammalian cell types. The synthetic fragment TB-500 replicates the actin-binding domain of the full protein, which is central to its biological activity in research models.

Mechanism of Action

Actin Sequestration and Polymerization

The primary documented mechanism of TB-500 involves its interaction with the actin cytoskeleton. TB-500 binds to monomeric G-actin, preventing premature polymerization into F-actin filaments. This sequestration creates a pool of available actin monomers that can be rapidly deployed for cytoskeletal reorganization — a process essential for cell migration, wound closure, and tissue remodeling.

Cell Migration Promotion

In both in vitro scratch assays and in vivo wound models, TB-500 has been observed to promote directional cell migration. The mechanism appears related to its effects on actin dynamics: by maintaining a readily available pool of G-actin, cells at wound edges can rapidly extend lamellipodia and migrate into the wound space.

Anti-Inflammatory Observations

Several published studies have reported anti-inflammatory effects associated with TB-500 administration in preclinical models. In rodent cardiac injury models, TB-500 treatment was associated with reduced inflammatory cell infiltration and decreased expression of pro-inflammatory cytokines relative to controls. The mechanism underlying these observations has not been fully elucidated.

Research Applications

Wound Healing and Dermal Repair

The most established research application for TB-500 involves wound healing models. Multiple studies have demonstrated accelerated wound closure in rodent models, with increased angiogenesis (new blood vessel formation) at wound sites. These effects have been attributed to both the actin-related migration enhancement and upregulation of vascular endothelial growth factor.

Cardiac Injury Models

Published work in mouse models of myocardial infarction has shown that TB-500 administration post-injury was associated with reduced scar size and improved cardiac function metrics compared to untreated controls. These studies have generated significant interest in Tβ4 biology, though translation to human cardiac research remains in early stages.

Corneal and Ocular Research

TB-500 has been studied in corneal wound healing models, where its effects on epithelial cell migration are particularly relevant. This research has progressed further toward clinical investigation than most other applications, with the full-length Tβ4 protein having entered clinical trials for ophthalmic indications under the name RGN-259.

Limitations and Considerations

As with most peptide research, the TB-500 literature is predominantly preclinical. Rodent and cell culture models make up the vast majority of published data. The translation gap between these models and any human application remains significant.

Researchers should also note that TB-500 (the synthetic fragment) and full-length Thymosin Beta-4 are not identical in all contexts. While they share the actin-binding domain, the full protein contains additional functional regions that may contribute to biological effects observed in some studies.

Specifications

CAS Number: 77591-33-4. Form: Lyophilized powder. Purity: ≥98% (HPLC). Storage: -20°C. Available strength: 10 mg.

All TB-500 from Vial & Error Labs includes a lot-specific COA and GHS-compliant SDS. For research use only.

What is BPC-157?

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein found in human gastric juice. Its CAS number is 1628202-19-6, and it is supplied as a lyophilized powder for research use. The compound has generated significant interest in preclinical research since the early 1990s, primarily for its observed effects in tissue repair and cytoprotection models.

It is important to note upfront: BPC-157 is not approved by the FDA or any regulatory body for human use. All data referenced in this article comes from in vitro and animal studies. No human clinical trials have been completed to date.

Mechanism of Action

BPC-157’s mechanism remains a subject of active research, but several pathways have been consistently observed across published studies.

Nitric Oxide System Modulation

Multiple studies have demonstrated that BPC-157 interacts with the nitric oxide (NO) system. In rodent models, BPC-157 appears to modulate NO synthase activity, influencing vascular tone and blood flow to damaged tissues. This interaction has been observed in models of both NO-depleted and NO-excess states, suggesting a modulatory rather than purely stimulatory role.

Growth Factor Upregulation

Preclinical evidence suggests BPC-157 may upregulate several growth factors relevant to tissue repair, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and hepatocyte growth factor (HGF). In tendon and ligament injury models in rats, increased expression of these markers has been correlated with accelerated healing timelines compared to untreated controls.

Documented Research Applications

Gastrointestinal Models

The most extensively studied application of BPC-157 is in gastrointestinal research. Studies in rodent models have examined its effects on gastric ulcers (both NSAID-induced and stress-induced), inflammatory bowel disease models, esophageal damage, and intestinal anastomosis healing. The compound’s origin in gastric juice has made GI research a natural area of investigation.

Musculoskeletal Repair Models

A substantial body of preclinical work has examined BPC-157 in tendon, ligament, muscle, and bone healing models. Achilles tendon transection models in rats have shown accelerated tendon-to-bone healing with BPC-157 treatment compared to saline controls. Similar patterns have been observed in quadriceps muscle crush injury models and ligament repair studies.

Neuroprotective Models

More recent research has explored BPC-157 in central and peripheral nervous system injury models, including traumatic brain injury, spinal cord injury, and peripheral nerve transection. While this body of work is smaller than the GI and musculoskeletal literature, published results have shown functional recovery improvements in treated groups versus controls.

What the Literature Supports — and What It Doesn’t

The preclinical evidence for BPC-157 is genuinely extensive — over 100 published studies spanning three decades. However, several important caveats apply.

First, nearly all published research is preclinical. Rodent models dominate the literature, and there is a notable absence of completed human clinical trials. This gap between preclinical promise and clinical validation is significant and should not be glossed over.

Second, much of the published work comes from a relatively small number of research groups, particularly from the University of Zagreb. While the quality of individual studies varies, the concentration of authorship is worth noting from a reproducibility standpoint.

Third, the dose-response relationship in animal studies does not translate directly to any human context. Extrapolating rodent dosages to human-equivalent doses is a common error in non-scientific discussions of BPC-157.

Handling and Storage

BPC-157 is supplied as a lyophilized (freeze-dried) powder. It should be stored at -20°C in a desiccated environment prior to reconstitution. Once reconstituted in bacteriostatic water or sterile saline, aliquots should be stored at 4°C and used within a reasonable timeframe to minimize degradation. As with all peptides, avoid repeated freeze-thaw cycles.

Specifications at a Glance

CAS Number: 1628202-19-6. Molecular Formula: C₆₂H₉₈N₁₆O₂₂. Form: Lyophilized powder. Purity: ≥98% (HPLC). Storage: -20°C.

All BPC-157 supplied by Vial & Error Labs ships with a lot-specific Certificate of Analysis and GHS-compliant Safety Data Sheet. For research use only — not for human or veterinary consumption.